Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00148902 · ClinicalTrials.gov registry record · Phase 1
Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)
A Phase 1 study of Neoplasms, Breast, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 2
- Study locations
NCT00148902: Completed Phase 1 study of Neoplasms, Breast, sponsored by GlaxoSmithKline.
NCT00148902 is a Phase 1 study of Neoplasms, Breast that has completed, run by GlaxoSmithKline. The registered enrollment target is 52 participants, below the 1,062-participant average among 9 other Neoplasms, Breast trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00148902, a Phase 1 study of Neoplasms, Breast, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a safety and tolerability study of GW572016 given with docetaxel (TAXOTERE).
Primary Outcome
An AE is any untoward medical occurrence in a subject or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-t
Conditions Studied
Interventions
- DRUG docetaxel
- DRUG lapatinib
Study Locations (2)
Michigan
- GSK Investigational Site - Detroit
Tennessee
- GSK Investigational Site - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2003-04-28 |
| Est. Completion | 2006-01-21 |
| Phase | Phase 1 |
What the finished NCT00148902 record still lists
NCT00148902 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 1,062-participant average among 9 other Neoplasms, Breast trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Neoplasms, Breast appearing as the primary indexed condition, and to 2 interventions - of which docetaxel is the first listed.
NCT00148902 reports a single indexed study location in Michigan, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00148902 about?
NCT00148902 is a clinical study titled "Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)". This is a safety and tolerability study of GW572016 given with docetaxel (TAXOTERE).
What is the current status of trial NCT00148902?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2003-04-28. Estimated completion is 2006-01-21.
What conditions does trial NCT00148902 study?
This clinical trial studies the following conditions: Neoplasms, Breast.
What interventions are being tested in trial NCT00148902?
The interventions under investigation include: docetaxel (DRUG), lapatinib (DRUG).
Who is sponsoring clinical trial NCT00148902?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00148902 being conducted?
This trial has 2 study locations across Michigan, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms, Breast
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00148902's enrollment target sits among peer trials
52 8th of 9 higher than 2 of 9 other Neoplasms, Breast trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms, Breast trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.
COMPLETED · Phase 1
-
A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer
COMPLETED · Phase 1
-
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
ACTIVE NOT RECRUITING · Phase 3
-
Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer
COMPLETED · Phase 3
-
Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC
COMPLETED · Phase 2
-
Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI